Cbl-b-IN-2
Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent[1].
Product Specifications
CAS Number
2503325-21-9
UNSPSC
12352005
Target
E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cbl-b-in-2.html
Purity
98.65
Solubility
DMSO : 140 mg/mL (ultrasonic)
Smiles
O=C1N(C2=CC=CC(C3(CC4=NN=CN4C)COC3)=C2)CC5=C1C=C(CN6C[C@@H](C)C(F)(F)CC6)C=C5C(F)(F)F
Molecular Formula
C29H30F5N5O2
Molecular Weight
575.57
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ACTH (Adrenocorticotrophic Hormone) (AH26), CF594 conjugate, 0.1mg/mL
